milvexian
bms
['factor xi', 'axiomatic', 'milvexian', '$bmy']
$bmy late-breaking results from phase 2 axiomatic-ssp study of milvexian, an investigational oral factor xia inhibitor, show favorable antithrombotic profile in combination with dual antiplatelet therapy 
Free Stock Market News are delayed 15 sec. Full features and live news available here: https://t.co/fWRacb3Vft